BMS' sBLA for 3rd-line SCLC drug granted FDA priority review status | FDA fast-tracks Calithera's advanced kidney cancer candidate | Amgen, Novartis' Aimovig benefits patients with treatment-resistant migraine
April 19, 2018
Bio SmartBrief
SIGN UP ⋅   FORWARD
Today's Top Story
BMS' sBLA for 3rd-line SCLC drug granted FDA priority review status
Bristol-Myers Squibb's supplemental biologics license application for Opdivo, or nivolumab, as a treatment for patients with small cell lung cancer with disease progression after two or more previous lines of therapy was accepted under FDA priority review status with an Aug. 16 PDUFA date. The application was backed by data from the Phase I/II CheckMate-032 study, in which single-agent Opdivo yielded an overall response rate of 10%, a median overall survival of 4.4 months and a one-year OS rate of 33% in 98 previously treated SCLC patients.
BioCentury (4/18) 
LinkedIn Twitter Facebook Google+ Email
2018 Life Sciences Accounting & Financial Reporting Update
How can life sciences companies keep pace with emerging accounting and financial reporting challenges? Learn about new accounting standards for revenue recognition, leases, and definition of a business and existing rules for R&D, income taxes and more. Download Deloitte's ninth annual update here.
ADVERTISEMENT
Health Care & Policy
FDA fast-tracks Calithera's advanced kidney cancer candidate
Calithera Biosciences' CB-839, in combination with Exelixis' Cabometyx, or cabozantinib, which is being developed as a treatment for patients with metastatic renal cell carcinoma who have failed up to two previous treatments, including at least one vascular endothelial growth factor tyrosine kinase inhibitor or a combination of Bristol-Myers Squibb's Yervoy, or ipilimumab, and BMS' Opdivo, or nivolumab, was given fast-track review status by the FDA.
Seeking Alpha (free registration) (4/18) 
LinkedIn Twitter Facebook Google+ Email
Amgen, Novartis' Aimovig benefits patients with treatment-resistant migraine
A Phase IIIb LIBERTY trial showed that Amgen and Novartis' Aimovig, or erenumab, had a significant treatment effect in patients with episodic migraine who had failed two to four previous treatments. In the trial, 30.3% of patients who received Aimovig experienced at least a 50% reduction in migraine days versus 13.7% for placebo.
PharmaTimes online (UK) (4/18) 
LinkedIn Twitter Facebook Google+ Email
New formulation of AZ, Daiichi's Nexium launched in Japan
AstraZeneca and Daiichi Sankyo introduced in Japan its proton pump inhibitor Nexium, or esomeprazole magnesium hydrate, in 10- and 20-mg granules for suspension, sachet, which is a new formulation of Nexium 10- and 20-mg capsules. The new therapy is indicated for the treatment of gastric, duodenal and anastomotic ulcers; reflux esophagitis; nonerosive reflux disease; Zollinger-Ellison syndrome; inhibition of recurrence of gastric or duodenal ulcer during low-dose aspirin administration; inhibition of recurrence of gastric or duodenal ulcer during nonsteroidal anti-inflammatory drug administration; and support of Helicobacter pylori eradication.
PharmaBiz (India) (4/19) 
LinkedIn Twitter Facebook Google+ Email
Japan gets access to Chugai's unresectable advanced/recurrent NSCLC therapy
Chugai Pharmaceutical's Tecentriq, or atezolizumab, intravenous infusion 1,200 mg was launched in Japan as treatment for patients with unresectable advanced or recurrent non-small cell lung cancer.
PharmaBiz (India) (4/19) 
LinkedIn Twitter Facebook Google+ Email
Company & Financial News
Novo Nordisk teams with Red Cross to fight chronic disease in conflict zones
Novo Nordisk teams with Red Cross to fight chronic disease in conflict zones
(Jean-Francois Monier/AFP/Getty Images)
Danish drug manufacturer Novo Nordisk is teaming up with the Red Cross to improve the treatment of chronic disease in conflict zones such as Syria and Yemen. Novo Nordisk has pledged a $3.58 million contribution and said it will supply the Red Cross with low-cost insulin, start projects aimed at combating diabetes and hypertension, and adapt production and ordering methods to further assist humanitarian organizations.
Reuters (4/18) 
LinkedIn Twitter Facebook Google+ Email
 
Follow-on funding pulls in $208M for MorphoSys
A follow-on funding pulled in $208 million for MorphoSys, which has plans of filing a rolling biologics license application to the FDA for relapsed or refractory diffuse large B cell lymphoma therapy MOR208 in the second half of 2019.
MedPage Today (free registration) (4/18),  BioCentury (4/18) 
LinkedIn Twitter Facebook Google+ Email
The Latest From BIO ...
Learn more about key policy issues affecting biotechnology in Washington, D.C., and state capitals around the country. With the unpredictability of the federal level coupled with the increasingly hostile state legislatures, it is vital that the biotechnology industry amplify its voice on the federal, state and local levels. Become an advocate for biotechnology by joining BIO Action today. Now, more than ever, we need your voice! Text BIO to 52886 or visit BIO's website.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Industry Deals
AiCuris partners with Max Planck to develop antibacterial drugs
The Max Planck Institute of Molecular Physiology agreed to work with AiCuris to discover and develop antibacterial drugs for the treatment of viral and bacterial infections. Under the collaboration, the institute's proprietary collection of natural product-based compounds will be used by AiCuris, and the two will jointly study compounds that have the potential to become anti-infective drugs.
Genetic Engineering & Biotechnology News (4/18) 
LinkedIn Twitter Facebook Google+ Email
Food & Agriculture
House Agriculture Committee advances Farm Bill; biotech crops addressed
The amended Farm Bill, which was recently approved by the House Agriculture Committee, would create a Biotechnology and Agricultural Trade Program to challenge foreign trade barriers that restrict the use of biotech commodities. The bill would also set up a national science-based education campaign to inform the public about the technologies used in food and agricultural production, and would require the Department of Agriculture to report to Congress its plans for improving the regulations on biotech products.
Agweek (4/18) 
LinkedIn Twitter Facebook Google+ Email
Industrial & Environmental
Japan to allow import of ETBE using US corn ethanol
Japan's government approved a policy that will allow imports of ethyl tert-butyl ether made from US corn ethanol. Under the policy, corn-based ethanol can comprise up to 44% of the country's 217 million-gallon ethanol demand for the production of ETBE, which is used in gasoline as an oxygenate.
DTN/The Progressive Farmer (4/17) 
LinkedIn Twitter Facebook Google+ Email
News From BIO
Rely on service that connects, consults and completes
The BIO and AirGas cost-savings program provides access to a nationwide network of local experts as a single-source supplier for medical and specialty gases, gas systems and cryogenic equipment. We care about your success as much as you care about your patients or research projects, and provide vital tools to assist your efforts. Whether conducting business on Airgas.com or taking advantage of one of our more customized eMarket solutions, Airgas gives you 24/7/365 access to your information on a convenient platform to optimize your back office systems. Learn more.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Press Releases
Post a Press Release
  
  
The sea does not reward those who are too anxious, too greedy or too impatient. ... One should lie empty, open, choiceless as a beach -- waiting for a gift from the sea.
Anne Morrow Lindbergh,
author and aviator
LinkedIn Twitter Facebook Google+ Email
  
  
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Sarah Hostetler
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information